Crigler-Najjar Syndrome Gene Therapy Gets EMA PRIME Designation
Three patients treated with Genethon’s GNT-003 were able to cease treatment with standard of care phototherapy for at least 1 year.
Genethon’s GNT-003 (GNT0003), an investigational adeno-associated virus (AAV) vector-based gene therapy being evaluated for the treatment of Crigler-Najjar syndrome in a phase 1/2 clinical trial (NCT03466463), has received priority medicines (PRIME) designation from the European Medicines Agency (EMA).1
Crigler-Najjar syndrome, an autosomal recessive inherited disorder, is caused by mutations in the UGT1A1 gene, which lead to decreased or absent UDP-glucuronosyltransferase enzyme levels.2 The lack of this enzyme leads to the build-up of unconjugated bilirubin. Currently, some patients with Crigler-Najjar syndrome are required to receive phototherapy for up to 12 hours per day in order maintain non-toxic bilirubin levels.1
GNT-003 is intended to provide a functional copy of the UGT1A1 gene. It is administered via intravenous injection. The EMA gave GNT-003 the PRIME designation based on early positive findings
“We’re excited about the EMA’s PRIME recognition of GNT-0003,” Frederic Revah, chief executive officer, Genethon, said in a statement regarding the news.1 “If successful, GNT-0003 would be the first gene therapy for Crigler-Najjar syndrome. The PRIME status is similar to the US FDA’s fast track and breakthrough designations. The EMA’s program was started in 2016 and in the first 5 years, only 25% of eligible drug candidates received the PRIME designation.”
In addition to GNT-003, Genethon is contributing to the development of gene therapies for several other indications. GNT-004, an investigational gene therapy for Duchenne muscular dystrophy, is being developed in collaboration with
Genethon has also developed GNT 0006, GNT 0007, and GNT 0008, for the treatment of limb girdle muscular dystrophy with FKRP deficiency, gamma sarco-glycanopathy, and calpainopathy, respectively.4 Genethon carried out preclinical development of GNT 0006, which demonstrated efficacy in preclinical animal research. The organization also performed a substantial portion of the preclinical research for GN 0007. Both GNT 0006 and GNT 0007 were licensed to Atamyo Therapeutics for clinical development. The organization noted that Atamyo Therapeutics is anticipating the submission of a clinical trial application for GNT 0007 in the near future. GNT 0008 has also been licensed to Atamyo Therapeutics, which will carry out the remainder of its preclinical development.
REFERENCES
1. Genethongiven PRIME status by EMA for gene therapy to treat Crigler-Najjar syndrome, a rare liver disease. News release. Genethon. March 6, 2023. Accessed March 7, 2023. https://www.genethon.com/app/uploads/2023/03/PRIME-Status_EMA_Gene_therapy_Crigler_N_23_03_06-1.pdf
2. Bhandari J, Thada PK, Yadav D. Crigler Najjar Syndrome. National Library of Medicine. Website Accessed January 10, 2023. https://www.ncbi.nlm.nih.gov/books/NBK562171/
3. Genethon. Duchenne muscular dystrophy. Website. Accessed March 7, 2023. https://www.genethon.com/our-pipeline/duchenne-muscular-dystrophy/
4. Genethon. Limb girdle muscular dystrophies. Website. Accessed March 7, 2023. https://www.genethon.com/our-pipeline/limb-girdle-muscular-dystrophies/
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025